Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Calcitriol / Calcipotriene

Classification: B

Drug products: Calcipotriol/Betamethasone Sandoz, Daivobet, Daivobet®, Daivonex, Daivonex®, Daivonex® Combipack, Dovobet, Dovobet®, Enstilar, Enstilar®, Kalcipotriol/Betametason Ebb, Xamiol, Xamiol®, Zoriaxiol

ATC code: D05AX02, D05AX52

Summary

No studies with a clinically relevant analysis of sex differences regarding pharmacokinetics or safety of calcitriol/calcipotriene have been found although a small study regarding effect of calcitriol/calcipotriene found no differences in time to remission.
 

Additional information

Pharmacokinetics and dosing

No difference between men and women has been shown for transdermal absorption in general [1].

Effects

In a study of patients with psoriasis vulgaris (43 men, 17 women) who had undergone narrowband ultraviolet B therapy and topical vitamin D3 (calcitriol/calcipotriene or maxacalcitol) the remission period from end of treatment to re-exacerbation was found to be similar in men and women [2].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of calcitriol/calcipotriene have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Other information

In a study of children with psoriasis (74 boys, 51 girls) (60 were treated with calcitriol/calcipotriene, unknown distribution of boys and girls) showed that the boys were more severely affected than the girls [3].

A US survey study from 1994 to 2001 in (2,109,075 men, 3,721,931 women) showed a peak in calcitriol/calcipotriene use in women during the first three years after its introduction 1994 and a large use off label, but after four years from introduction the use became quite similar in men and women [4].

A database including patients (469 men, 568 women) from outpatient clinics specialized in chronic pruritus showed sex and gender differences in etiology, presentation and impact and quality of life of the disease [5].

Updated: 2017-06-19

Date of litterature search: 2017-05-10

References

  1. Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21. PubMed
  2. Karakawa M, Komine M, Takekoshi T, Sakurai N, Minatani Y, Tada Y et al. Duration of remission period of narrowband ultraviolet B therapy on psoriasis vulgaris. J Dermatol. 2011;38:655-60. PubMed
  3. Stefanaki C, Lagogianni E, Kontochristopoulos G, Verra P, Barkas G, Katsambas A et al. Psoriasis in children: a retrospective analysis. J Eur Acad Dermatol Venereol. 2011;25:417-21. PubMed
  4. Pearce DJ, Camacho F, Balkrishnan R, Fleischer AB, Feldman SR. Trends in on and off-label calcipotriene use. J Dermatolog Treat. 2006;17:308-13. PubMed
  5. Ständer S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168:1273-80. PubMed
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.] länk

Authors: Maria Enghag

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson